Results 1 to 10 of about 57,701 (138)
Zhongliu Fangzhi Yanjiu, 2021 Objective To investigate the inhibitory effect and mechanism of temozolomide on migration and invasion of U251 human glioma cells enhanced by plumbagin.
CAI Wei +5 more
doaj +1 more source
Identification and verification of the temozolomide resistance feature gene DACH1 in gliomas
Frontiers in Oncology, 2023 IntroductionThe most important chemotherapy treatment for glioma patients is temozolomide. However, the development of drug resistance severely restricts the use of temozolomide.
Qiang Gu +7 more
doaj +1 more source
Thermodynamic properties of temozolomide in crystalline and gaseous aggregate states
Журнал Белорусского государственного университета: Химия, 2022 Temozolomide (4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4,3,0]nona-2,7,9-triene-9-carboxamide) is an active component of antitumor immunosuppressive alkylating drugs, and it used largely for the treatment of various types of malignant tumors, including ...
Yana N. Yurkshtovich, Andrey V. Blokhin
doaj +1 more source
American Journal of Neuroradiology, 2010 Temozolomide, an oral alkylating agent, is a commonly used medicine in the treatment of anaplastic astrocytoma and glioblastoma multiforme. This paper will present the mechanism of action as well as the clinical role for this chemotherapeutic drug.
J R, Wesolowski +2 more
openaire +2 more sources
Salvage temozolomide for prior temozolomide responders [PDF]
Cancer, 2005 AbstractBACKGROUNDTemozolomide (TMZ) often is used as adjuvant or first‐line therapy for patients with glioma. Because of potential hematologic complications, it usually is discontinued after 12–18 cycles, even in responders. Subsequent salvage therapies are reported to have limited efficacy at the time of disease recurrence.
Enrico, Franceschi +5 more
openaire +2 more sources
BMC Chemistry, 2023 In this article for the first time the quantum calculations of 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide (Temozolomide) in HCM-Cellulose Substrate are evaluated using the B3LYP/6-31G level of theory.
Masoumeh Shahi, Fatemeh Azarakhshi
doaj +1 more source
Acute toxicity of temozolomide for the treatment of anaplastic astrocytoma: A case report
Glioma, 2021 Temozolomide is an orally administered chemotherapeutic drug that has become a standard treatment for malignant gliomas. Severe toxicity of temozolomide is rare, especially shortly after administration. We report a 37-year-old male patient diagnosed with
Yunni Diansari +2 more
doaj +1 more source
XPA Enhances Temozolomide Resistance of Glioblastoma Cells by Promoting Nucleotide Excision Repair
Cell Transplantation, 2022 Glioblastoma is the most frequent, as well as aggressive kind of high-grade malignant glioma. Chemoresistance is posing a significant clinical barrier to the efficacy of temozolomide-based glioblastoma treatment.
Weimin Dai +4 more
doaj +1 more source
Should CD4 Levels be Monitored in a Patient on Temozolomide?
European Journal of Case Reports in Internal Medicine, 2021 Introduction: Temozolomide is an alkylating agent, indicated in the treatment of refractory anaplastic astrocytoma and newly diagnosed glioblastoma. We describe a case of Salmonella typhimurium bacteraemia associated with septic arthritis in the setting ...
Sriram Gonakoti, Luis Parra-Rodriguez
doaj +1 more source
Frontiers in Pharmacology, 2022 Glioblastoma multiform is the most aggressive primary type of brain tumor, representing 54% of all gliomas. The average life span for glioblastoma multiform is around 14–15 months instead of treatment.
Priya Bisht +4 more
doaj +1 more source